PTHS · CIK 0001919246 · operating
Pelthos Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for conditions with limited treatment options. The company's marketed product ZELSUVMI is indicated for molluscum contagiosum in adults and children ages one year and older. The company also operates NITRICIL, a proprietary nitric oxide-based technology platform designed to support product development across its pipeline.
The company generates revenue primarily through product sales and commercialization activities related to ZELSUVMI. Pelthos maintains a small operational footprint with four full-time employees and is headquartered in Durham, North Carolina. The company was incorporated in Nevada and trades on the New York Stock Exchange with a market capitalization of approximately $100 million. Originally founded in 2002 as Channel Therapeutics Corporation, the company rebranded to Pelthos Therapeutics in July 2025.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.43 | $-1.43 | -124.7% | |
| 2023 | — | $5.78 | — |